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Summary
Acute RyR2 activation by exchange protein directly activated by cAMP (Epac) reversibly 
perturbs myocyte Ca2+ homeostasis, slows myocardial action potential conduction, and 
exerts pro- arrhythmic effects. Loose patch- clamp studies, preserving in vivo extracellular 
and intracellular conditions, investigated Na+ current in intact cardiomyocytes in murine 
atrial and ventricular preparations following Epac activation. Depolarising steps to vary-
ing test voltages activated typical voltage- dependent Na+ currents. Plots of peak current 
against depolarisation from resting potential gave pretreatment maximum atrial and ven-
tricular currents of −20.23 ± 1.48 (17) and −29.8 ± 2.4 (10) pA/μm2 (mean ± SEM [n]). 
Challenge by 8- CPT (1 μmol/L) reduced these currents to −11.21 ± 0.91 (12) (P < .004) 
and −19.3 ± 1.6 (11) pA/μm2 (P < .04) respectively. Currents following further addition of 
the RyR2 inhibitor dantrolene (10 μmol/L) (−19.91 ± 2.84 (13) and −26.6 ± 1.7 (17)), and 
dantrolene whether alone (−19.53 ± 1.97 (8) and −27.6 ± 1.9 (14)) or combined with 8- 
CPT (−19.93 ± 2.59 (12) and −29.9 ± 2.5(11)), were indistinguishable from pretreatment 
values (all P >> .05). Assessment of the inactivation that followed by applying subsequent 
steps to a fixed voltage 100 mV positive to resting potential gave concordant results. 
Half- maximal inactivation voltages and steepness factors, and time constants for Na+ cur-
rent recovery from inactivation in double- pulse experiments, were similar through all the 
pharmacological conditions. Intracellular sharp microelectrode membrane potential re-
cordings in intact Langendorff- perfused preparations demonstrated concordant varia-
tions in maximum rates of atrial and ventricular action potential upstroke, (dV/dt)max. We 
thus demonstrate an acute, reversible, Na+ channel inhibition offering a possible mecha-
nism for previously reported pro- arrhythmic slowing of AP propagation following modifi-
cations of Ca2+ homeostasis, complementing earlier findings from chronic alterations in 
Ca2+ homeostasis in genetically- modified RyR2-P2328S hearts.
K E Y W O R D S
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1  | INTRODUCTION
Cardiac arrhythmias result from disruptions in the normal excitable 
activity propagating through successive structures in the heart. They 
arise from altered function in surface membrane ionic channels whose 
successive activation and inactivation underlies the production and 
propagation of cardiac action potentials (AP). Sustained arrhythmia 
may require both triggering events and arrhythmic substrate to main-
tain the resulting abnormal electrical activity.1–3 Arrhythmic substrate 
arises either from slowed myocardial AP conduction or activation, ex-
emplified by Brugada Syndrome,4,5 or altered AP recovery, reflected 
in altered AP duration and/or refractoriness, exemplified by long QT 
syndrome.6 Arrhythmic risk is also associated with dysregulated in-
tracellular Ca2+ homeostasis. This may arise from abnormal ryanodine 
receptor- 2 (RyR2)- mediated sarcoplasmic reticular Ca2+ release. The 
resulting elevations in diastolic [Ca2+] and spontaneous propagated 
intracellular Ca2+ waves increase electrogenic Na+- Ca2+ exchanger 
activity thereby driving delayed after- depolarisations that may trigger 
premature ventricular beats.7
Murine hearts carrying genetically altered RyR2- Ca2+ release 
channel and SR Ca2+ storage protein calsequestrin- 2 have success-
fully modelled such triggering events. They recapitulate mutations 
associated with the chronic pro- arrhythmic condition of human 
catecholaminergic polymorphic ventricular tachycardia (CPVT).8,9 
Triggering events have also been reported following acute adrener-
gic activation produced by modifications of RyR2- mediated SR Ca2+ 
release10 and surface Ca2+ channel properties in wild-type hearts ex-
pressing normal RyR2 and calsequestrin- 2.11,12 More recent studies 
selectively activated RyR2- Ca2+ release channels using the phos-
phokinase A (PKA)- independent exchange protein directly activated 
by cAMP (Epac) pathway.13–15 This increased Ca2+ spark frequencies 
in adult rat cardiac myocytes16 and amplitudes of Ca2+- dependent 
Ca2+ release after isoproterenol treatment17 in murine ventricular 
cardiomyocytes. They also increased the amplitudes and frequen-
cies of spontaneous Ca2+ release.18 These changes correlated with 
increases in triggered activity and ventricular tachycardia (VT) in 
murine hearts.18
Fewer studies have explored arrhythmic substrate under con-
ditions of altered Ca2+ homeostasis. Neither chronic modifications 
in Ca2+ homeostasis in RyR2-P2328S models nor acute manip-
ulations of Ca2+ homeostasis in WT hearts altered AP recovery 
characteristics as reflected in AP durations (APD), refractory pe-
riods (ERP), or the relationships between these.8,12,19 However, 
murine RyR2-P2328S CPVT cardiac models showed reduced 
atrial20 and ventricular conduction velocities in common with 
Nav1.5- haploinsufficient Scn5a+/− hearts modelling the Brugada 
Syndrome.21 Pharmacological inhibition of RyR2- mediated Ca2+ re-
lease with flecainide partly rescued these effects.22–25 Furthermore, 
selective, acute RyR2 activation through the Epac pathway pro-
duced parallel pro- arrhythmic effects.18 It correspondingly pro-
duced decreases in AP conduction velocities that were partially 
reversed by the RyR2 antagonist dantrolene, with an absence of 
alterations in AP recovery characteristics.19
The mechanism for the conduction velocity changes in RyR2-
P2328S hearts was identified as the direct action of intracellular 
Ca2+ on Nav1.5 function
20,21,26 and/or Nav1.5 membrane expres-
sion.27 However, the mechanisms by which acute manipulations of 
intracellular Ca2+ homeostasis, particularly Epac activation, alter AP 
conduction have not been investigated. The present experiments 
assessed Nav1.5 activation, inactivation, and recovery from inac-
tivation following acute rather than chronic manipulations of Ca2+ 
homeostasis, and in WT rather than genetically- modified hearts. 
They employed the loose patch technique for voltage- clamping 
of Na+ current. This apposes an electrode containing extracellular 
solution against an intact cell surface membrane without accessing 
intracellular space. Studies were thus performed in cardiomyocytes 
in intact murine atrial and ventricular preparations without perturb-
ing extracellular [Na+] and intracellular Ca2+ homeostasis21,28,29 as 
opposed to following cardiomyocyte isolation necessitated by con-
ventional whole- cell patch clamp techniques.30,31
Recent cardiomyocyte studies involving reversible manipulations 
of loose patch pipette [Na+] had identified early inward currents in 
response to step depolarisations with Na+ currents responsible for AP 
conduction and the maximum upstroke rate, (dV/dt)max, of the cardiac 
action potential.21 The corresponding changes in such (dV/dt)max were 
accordingly determined by independent experiments performing in-
tracellular sharp electrode recordings of membrane potential in intact 
atrial and ventricular preparations. These explored the extent to which 
changes in observed (dV/dt)max, paralleled corresponding changes in 
Na+ currents in the loose- patch experiments with similar pharma-
cological manipulations. Such correlations would be consistent with 
previously reported relationships between (dV/dt)max and peak Na
+ 
currents (INa).
32
We thus studied electrophysiological effects of pharmacolog-
ical manipulations of Ca2+ homeostasis through Epac activation 
on Na+ currents in a near physiological environment for the first 
time. The Epac activator (8- pCPT- 2′- O- Me- cAMP: 8- (4- chlorophe
nylthio)- 2′- O- methyladenosine- 3′,5′- cyclic monophosphate)13 at 
approximately 1 μmol/L offered 300- fold preferential selectivity 
for Epac over PKA action.13,33–35 The RyR2 antagonist dantrolene 
inhibits RyR2- mediated diastolic Ca2+ release, decreases frequen-
cies and durations of aberrant Ca2+ sparks in myocyte cultures 
modelling CPVT36 and cardiac failure37,38 and increases thresholds 
for Ca2+- induced sarcoplasmic reticular Ca2+- release in myocytes 
from failing but not normal rabbit hearts.38 Thus, both 8- CPT and 
dantrolene act on intracellular targets following access across car-
diomyocyte surface membrane as a whole whether during loose- 
patch or sharp electrode recordings. Finally, the results obtained 
with the approach adopted here could be directly compared to 
corresponding explorations in intact Langendorff perfused mu-
rine hearts. In addition to establishing the expected alterations in 
cellular Ca2+ homeostasis, they used identical Epac activators and 
RyR2 antagonists in identical pharmacological protocols exploring 
the effects of Epac activation and their reversibility applying these 
to examine changes in AP conduction velocity and arrhythmic 
substrate.18,19
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2  | RESULTS
2.1 | Currents obtained in the combined pulse 
procedure
Figures 1 and 2 illustrate results obtained from the isolated atrial 
(Figure 1) and ventricular (Figure 2) preparations subject to a com-
bined pulse procedure (Panel Aa) designed to explore both activation 
and inactivation properties of Na+ currents. Cells were first held at the 
resting membrane potential (RMP) for 5 ms from the beginning of the 
recording period. A prepulse of duration 5 ms to V0 = (RMP−40) mV 
was then applied to remove any residual Na+ current inactivation 
and standardise the initial activation state of Na+ channels within the 
patch. Na+ current activation properties were then investigated using 
the initial depolarising test voltage steps made to a voltage varied with 
the 13 successive sweeps between V1 = RMP to (RMP + 120) mV in 
+10 mV increments. These currents, following correction for residual 
leakage by a P/4 protocol, provided a family of records reflecting the 
voltage dependence of Na+ channel activation (Panels Ab and Ba). 
Inward currents are represented as downward, negative deflections. 
Records typically began with a consistent small upward deflection in 
response to the −40 mV prepulse. The subsequent voltage steps to 
level V1 yielded a family of inward currents initially increasing with 
time to a peak value that increased as V1 was made more positive. This 
was followed by a decay reflecting channel inactivation whose extent 
and kinetics was similarly determined by the voltage V1.
The subsequent voltage steps in the pulse protocol were used to 
assess properties of the Na+ current inactivation resulting from the 
voltage step to V1. Thus, 5 ms following imposition of the latter step, an 
additional step was applied to a fixed voltage of V2 = (RMP + 100) mV 
that would result in a peak Na+ current reflecting the extent of the 
preceding channel inactivation (Panels Ab and Ca). The step to voltage 
V2 thus elicited a second family of currents which decreased in am-
plitude with increasing V1. Both sets of responses showed nonlinear 
F IGURE  1  Ionic currents from an 
isolated atrial preparation studied under 
loose- patch clamp. (Aa) Pulse protocol 
designed to investigate Na+ channel 
activation and inactivation. (Ab) Typical 
recordings obtained using with a pipette of 
28 μm tip diameter. Inward currents in nA 
are represented as negative. All currents 
shown in subsequent panels converted 
to current density in units of (pA/μm2) to 
account for pipette diameters, typically 28- 
32 μm. (B, C) Na+ currents observed upon 
(B) activation by depolarisation to a level 
V1, before and following pharmacological 
challenge and (C) in response to the voltage 
step from levels V1 to the final level V2. 
The latter permitted assessment of Na+ 
channel inactivation produced by the 
voltage step to level V1. Recordings made 
(a) under pretreatment conditions, when 
no drug was present, (b) in the presence 
of 8- CPT (1 μmol/L), (c) in the presence 
of a combination of 8- CPT (1 μmol/L) and 
dantrolene (10 μmol/L) after the addition of 
8- CPT, (d) after the addition of dantrolene 
(10 μmol/L), and (e) in the presence of 
a combination of 8- CPT (1 μmol/L) and 
dantrolene (10 μmol/L). (d) and (e) were 
obtained following direct introduction 
of pharmacological agents following 
pretreatment conditions in the absence of 
any preceding application of 8- CPT
(B)
(A)
a
b V0 V1 V2
10 ms
100 mV
10 ms
5 nA
a Control
a Control
b 8-CPT
b 8-CPT
c 8-CPT + dantrolene
d dantrolene
e 8-CPT + dantrolene
c 8-CPT + dantrolene
e 8-CPT + dantrolene
d dantrolene
1 ms
1 ms
10  pA/μm2
10  pA/μm2
(C)
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increments in the magnitude of currents obtained at successive volt-
ages reflecting the nonlinear dependence of either activation or inac-
tivation about the voltage V1.
2.2 | Currents reflecting Na+ channel activation
Figures 1B and 2B show typical families of current records illus-
trating Na+ current activation obtained in response to the initial 
steps between voltages V0 and V1 in atrial (Figure 1) and ventricu-
lar (Figure 2) preparations. In both panels B and C currents are nor-
malised to the area subtended by the pipette tip lumen (in μm2) to 
give current densities. Recordings were made before (pretreatment: 
Panel Ba), and following challenge by 8- CPT (1 μmol/L) (Bb), and 
then 8- CPT (1 μmol/L) combined with dantrolene (10 μmol/L) (Bc). 
These were compared with records obtained following challenge by 
dantrolene (10 μmol/L) alone (Bd) and in combination with 8- CPT 
(1 μmol/L) (Be).
The pretreatment Na+ currents showed typical activation and inacti-
vation time courses with their amplitude nonlinearly graded with the size 
of the depolarising step (Ba). 8- CPT markedly decreased the Na+ current 
amplitudes at all test voltages in both atrial and ventricular preparations 
(Bb). However, further inclusion of dantrolene in the test solutions res-
cued the Na+ current, reversing the inhibitory action of 8- CPT alone (Bc). 
These findings were corroborated by another control procedure. Thus, 
families of currents before treatment (Ba) were recorded and the pretreat-
ment solution then replaced by one including dantrolene either alone (Bd) 
or combined with 8- CPT (Be). All these conditions (Ba, Bd, Be) gave similar 
Na+ currents. Thus, 8- CPT reduces Na+ current in both atrial and ventricu-
lar preparations, but this action was reversed or absent in the presence of 
dantrolene whether by itself or in combination with 8- CPT.
F IGURE  2  Ionic currents from an 
isolated ventricular preparation studied 
under loose- patch clamp. (Aa) Pulse 
protocol designed to investigate Na+ 
channel activation and inactivation. (Ab) 
Typical recordings obtained using with 
a pipette of tip diameter 30 μm. Inward 
currents in nA represented as negative. 
All currents shown in subsequent figures 
have been converted to current density in 
units of (pA/μm2) to account for pipette 
diameters, typically 28- 32 μm. (B, C) Na+ 
currents observed upon (B) activation by 
depolarisation to a level V1, before and 
following pharmacological challenge and (C) 
in response to the voltage step from levels 
V1 to the final level V2. The latter permitted 
assessment of Na+ channel inactivation 
produced by the voltage step to level V1. 
Recordings made (a) under pretreatment 
conditions, when no drug was present, (b) 
in the presence of 8- CPT (1 μmol/L), (c) in 
the presence of a combination of 8- CPT 
(1 μmol/L) and dantrolene (10 μmol/L) 
after the addition of 8- CPT, (d) after the 
addition of dantrolene (10 μmol/L), and (e) 
in the presence of a combination of 8- CPT 
(1 μmol/L) and dantrolene (10 μmol/L). 
(d) and (e) were obtained following direct 
introduction of pharmacological agents 
following pretreatment conditions in the 
absence of any preceding application of 
8- CPT
(A)
10 ms
10 ms.100 
mV
a
b
5 nA
(B)
a Control
b 8-CPT
c 8-CPT + dantrolene
d dantrolene
e 8-CPT + dantrolene
1 ms
10  pA/μm2
(C)
d dantrolene
a Control
b 8-CPT
c 8-CPT + dantrolene
e 8-CPT + dantrolene
1 ms
10  pA/μm2
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2.3 | Currents reflecting Na+ channel inactivation
Records demonstrating typical families of Na+ current inactivation 
from atrial and ventricular preparations are shown in Figures 1C and 
2C. Each family of records was obtained from an individual patch in 
response to the steps between the voltages V1 and V2 (panel Aa). 
These illustrate the extent of Na+ channel inactivation resulting from 
the step to voltage V1. Only the fraction of channels spared such in-
activation would then be activated by the step to the fixed voltage V2. 
The Na+ current amplitudes would therefore permit quantification of 
the voltage dependence of Na+ channel inactivation at the voltage V1. 
Records were obtained before 8- CPT challenge (pretreatment) (Ca), 
following 8- CPT challenge (Cb), and following challenge by 8- CPT 
combined with dantrolene (Cc). They were compared with results of 
transferring pretreatment preparations directly to solutions contain-
ing dantrolene alone (Cd) or dantrolene combined with 8- CPT (Ce). 
The resulting Na+ currents showed typical activation and inactivation 
time courses, but these decreased in amplitude the more depolarised 
the voltage V1 (Ca). Again, 8- CPT markedly decreased Na
+ current am-
plitudes at all voltages tested (Cb), and further inclusion of dantrolene 
restored the Na+ currents (Cc). Na+ currents following challenge by 
dantrolene alone (Cd) or dantrolene in combination with 8- CPT (Ce) 
were similar in amplitude and waveform as pretreatment records. 
Thus, the pulse procedures assessing current inactivation similarly 
demonstrated that 8- CPT reduced Na+ current amplitude and this ac-
tion was rescued by further addition of dantrolene.
2.4 | Voltage dependences of atrial Na+ current 
activation and inactivation
Figures 3 and 4 illustrate voltage- dependences of atrial (Figure 3) 
and ventricular (Figure 4) Na+ current activation (A) and inactiva-
tion (B) under each of the experimental conditions described above 
(a–c). They plot the peak Na+ current (mean ± standard error of the 
mean [SEM]) against the voltage V1. Results are shown for pretreat-
ment conditions (open symbols) and following addition of 8- CPT 
(filled triangles) and 8- CPT combined with dantrolene (filled circles) 
(a). These results were compared with findings obtained before and 
following addition of dantrolene alone (pretreatment: open symbols; 
dantrolene: filled diamonds) (b) and before and following addition of 
dantrolene in combination with 8- CPT (pretreatment: open symbols; 
8 CPT with dantrolene, filled circles) (c). In both atrial (Figure 3) and 
the ventricular preparations (Figure 4) peak current increased with 
the amplitudes of depolarising steps exceeding +10 mV in size to a 
maximum value at a voltage excursion around +80 mV. They then 
decreased with further depolarisation as expected with approach of 
F IGURE  3 Voltage dependence of atrial Na+ current activation and inactivation under the different pharmacological conditions employing 
8- CPT and dantrolene. Dependences of (A) Na+ current activation (mean ± SEM) upon voltage step V1, before (pretreatment) and following 
pharmacological challenge and (B) Na+ current inactivation (mean ± SEM) as a function of voltage step V1, assessed using the further voltage 
step V2, before and after pharmacological challenge. Results obtained (a) before (open squares) and following introduction of 8- CPT (filled 
triangles) and a combination of 8- CPT and dantrolene (filled circles), (b) before (open squares) and following introduction of dantrolene (filled 
diamonds), (c) before (open squares) and following introduction of a combination of 8- CPT and dantrolene (filled circles)
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V1 towards the Na
+ current reversal potential. Table 1 summarizes the 
results of applying voltage steps of a fixed +80 mV amplitude, em-
ploying 12 signal- averaged records, to explore the effect of the dif-
ferent pharmacological agents on such maximum peak current under 
the different pharmacological conditions. The presence of significant 
differences in both atrial (F = 3.462, P = .013) and ventricular find-
ings between experimental groups (F = 4.071, P = .006) prompted 
pairwise testing demonstrating differences between results of expo-
sure to 8- CPT compared to findings from untreated patches in both 
atrial (P < .04) and ventricular cardiomyocytes (P < .004; α = .05). In 
contrast, there were no detectable differences (P > .2) of findings ob-
tained with challenge by 8- CPT followed by 8- CPT combined with 
dantrolene, and dantrolene whether alone, or combined with 8- CPT, 
when all were compared from data from untreated patches.
These findings from Table 1 were corroborated by the correspond-
ing atrial and ventricular Na+ current- voltage curves. Peak atrial cur-
rents increased with depolarisation to approximately −18.5 ± 1.8 pA/
μm2 (n = 13) (Figure 3Aa) and −13.5 ± 1.3 pA/μm2 (n = 14) before and 
following 8- CPT challenge. In contrast, currents following further ad-
dition of dantrolene (−22.5 ± 3.9 pA/μm2 [n = 6]) (Aa), or exposure 
to dantrolene either alone (−20.2 ± 1.9 pA/μm2 [n = 11]) (Ab), or 
combined with 8- CPT (−22.7 ± 1.9 pA/μm2 [n = 7]) (Ac) were similar 
to pretreatment values. Similar results emerged from atrial Na+ cur-
rent inactivation studies of peak Na+ current in response to voltage 
steps from V1 to the fixed level V2, plotted against inactivating volt-
age V1 (Figure 3B). Maximum currents at the most negative V1 before 
treatment (−19.1 ± 1.7 pA/μm2 [n = 13]) fell (to −13.6 ± 0.9 pA/μm2 
[n = 14] (P < .01)) with 8- CPT challenge, whereas currents observed 
following further addition of dantrolene (−22.0 ± 3.3 pA/μm2 [n = 5]) 
(Ba), or exposure to dantrolene whether alone (Bb), or combined 
with 8- CPT (Bc) (−19.4 ± 1.8 pA/μm2 [n = 11] and −21.4 ± 1.8 pA/
μm2 [n = 8] respectively) approximated pretreatment values. These 
changes occurred in an absence of alterations in fits of a Boltzmann 
function to the inactivation curves. Neither half- maximal voltages, V* 
(54.9 ± 2.1 mV [pretreatment], 55.8 ± 2.1 mV (8- CPT); 55.7 ± 6.8 mV 
[addition of dantrolene to 8- CPT]; 55.7 ± 3.2 mV [dantrolene] and 
58.6 ± 2.2 mV [dantrolene with 8- CPT]), nor steepness factors, k, 
(13.2 ± 0.6 mV, 15.3 ± 0.7 mV, 14.4 ± 0.83 mV, 14.1 ± 0.6 mV, and 
15.1 ± 0.5 mV respectively) showed significant differences between 
groups.
F IGURE  4 Voltage dependence of ventricular Na+ current activation and inactivation under the different pharmacological conditions 
employing 8- CPT and dantrolene. Dependences of (A) Na+ current activation (mean ± SEM) upon voltage step V1, before (pretreatment) and 
following pharmacological challenge and (B) Na+ current inactivation (mean ± SEM) as a function of voltage step V1 assessed using the further 
voltage step V2, before and after pharmacological challenge. Results obtained (a) before (open squares) and following introduction of 8- CPT 
(filled triangles) and a combination of 8- CPT and dantrolene (filled circles), (b) before (open squares) and following introduction of dantrolene 
(filled diamonds), (c) before (open squares) and following introduction of a combination of 8- CPT and dantrolene (filled circles)
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2.5 | Voltage dependences of ventricular Na+ current 
activation and inactivation
Current- voltage curves describing voltage dependences of ven-
tricular Na+ current activation (Figure 4A) similarly corroborate re-
sults in Table 1. Peak Na+ currents increased with depolarisation 
to −27.0 ± 2.8 pA/μm2 (n = 11) (Figure 4Aa) under pretreatment 
conditions but only to −16.8 ± 1.6 pA/μm2 (n = 10) in the presence 
of 8- CPT. However, currents following further addition of dantrolene 
(−24.4 ± 1.7 pA/μm2 [n = 10]) (Aa), or exposure to dantrolene whether 
alone (−26.6 ± 2.0 pA/μm2) (n = 12) (Ab), or combined with 8- CPT 
(−25.1 ± 2.2 pA/μm2) (n = 11) (Ac) approximated pretreatment values. 
Protocols exploring Na+ current inactivation with voltage V1, reflected 
in currents observed at voltage V2 demonstrated currents at the most 
Pharmacological condition
Maximum currents, (Mean ± SEM (n–value), pA/μm2
Atrial preparation Ventricular preparation
(a) Untreated −20.23 ± 1.48 (n = 17)*** −29.8 ± 2.4 (n = 10)**
(b) 8–CPT −11.21 ± 0.91 (n = 12)*** −19.3 ± 1.6 (n = 11)**
(c) 8–CPT followed by 
8–CPT + dantrolene
−19.91 ± 2.84 (n = 13) −26.6 ± 1.7 (n = 17)
(d) Dantrolene alone −19.53 ± 1.97 (n = 8) −27.6 ± 1.9 (n = 14)
(e) 8–CPT + dantrolene −19.93 ± 2.59 (n = 12) −29.9 ± 2.5 (n = 11)
8–(4–chlorophenylthio) adenosine 3′,5′–cyclic monophosphate (8–CPT, 1 μmol/L); dantrolene 
(10 μmol/L). One- way ANOVA: atrial preparations: F = 3.462, P = .013; ventricular preparations: 
F = 4.071, P = .006. Posthoc comparisons (after Bonferroni correction for four pairwise tests): **P < .04; 
***P < .004, relative to untreated group; no significant changes in all remaining groups (c)–(e) compared 
to control: P > .2.
TABLE  1 Maximum inward currents in 
atrial and ventricular preparations under 
the tested pharmacological conditions
F IGURE  5 Time course of atrial Na+ current recovery from inactivation. (Aa) Pulse protocols used to investigate the time course of Na+ 
current recovery from inactivation (Ab) Recovery of Na+ currents with time after inactivation. A pipette of tip diameter 28 μm was used to obtain 
the currents shown in (b). (B) Families of recovery currents recorded (a) when no drug was present (pretreatment), (b) in the presence of 8- CPT 
(1 μmol/L), (c) in the presence of a combination of 8- CPT (1 μmol/L) and dantrolene (10 μmol/L) after the addition of 8- CPT, (d) after the addition 
of dantrolene (10 μmol/L), and (e) in the presence of a combination of 8- CPT (1 μmol/L) and dantrolene (10 μmol/L). (d) and (e) were obtained 
following direct introduction of pharmacological agents following pretreatment conditions in the absence of any preceding application of 8- CPT. 
(C) Dependences of Na+ current recovery (mean ± SEM) with recovery time before and following pharmacological challenge. The graphs show 
results (a) before and (b) following introduction of 8- CPT followed by (c) a combination of 8- CPT and dantrolene, (d) dantrolene alone and (e) a 
combination of 8- CPT and dantrolene
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negative V1 before treatment (−16.7 ± 1.4 pA/μm
2 [n = 7]) falling (to 
−13.1 ± 1.1 pA/μm2 [n = 9]) with 8- CPT challenge. However, currents 
following further addition of dantrolene (−16.4 ± 1.7 pA/μm2 [n = 7]) 
(Ba), or exposure to dantrolene whether alone (Bb), or combined 
with 8- CPT (Bc) (−17.6 ± 1.2 pA/μm2 [n = 12] and −16.3 ± 1.6 pA/
μm2 [n = 8] respectively) approximated pretreatment values (all 
P > .05). These changes occurred in an absence of alterations in 
fits of a Boltzmann function to the inactivation curves. Neither V* 
nor k showed significant differences between experimental groups 
(46.0 ± 3.5, 11.2 ± 1.4 [pretreatment]; 50.3 ± 2.3, 10.0 ± 0.4 [8- CPT]; 
53.4 ± 2.1, 9.8 ± 0.5 [addition of dantrolene to 8- CPT]; 42.5 ± 1.4, 
11.7 ± 0.6 [dantrolene alone] and 45.6 ± 1.9, 10.8 ± 0.5 mV [dant-
rolene with 8- CPT]).
2.6 | Time course of Na+ channel recovery from 
inactivation
The subsequent protocols investigated timecourse of Na+ channel 
recovery from inactivation following atrial or ventricular repolari-
sation (Figures 5A and 6A) under the same set of pharmacological 
conditions as described above. The voltage was held at the RMP 
for 1 ms from the beginning of the recording period before impo-
sition of a hyperpolarising prepulse to voltage V0 = (RMP−40) mV 
for 4 ms. This established a consistent baseline level of Na+ current 
inactivation as in the previous protocol (Figures 5 and 6; panel Aa). 
A P1 conditioning step between V0 and V1 = (RMP + 80) mV of 5 ms 
duration then elicited activation of an initial Na+ current followed by 
its inactivation decay (Figures 5 and 6, panel Ab, B). Depolarising P2 
steps of 5 ms duration to voltage V3 = (RMP + 80) mV were then im-
posed following different time intervals, T, which varied between 5 
to 65 ms in 5 ms increments through the 12 successive sweeps mak-
ing up the protocol. These P2 steps could be used to assess the re-
covery with time of the peak Na+ current from inactivation (Ab). The 
peak currents are normalized to their values obtained in the P1 step 
(Figures 5C and 6C). Fits of time constants to this recovery gave sta-
tistically indistinguishable results (P > .05) in each case (a)–(e) (atria: 
4.58 ± 0.31 ms; 3.99 ± 0.38 ms; 3.90 ± 0.22 ms; 3.92 ± 0.38 ms and 
3.91 ± 0.25 ms; ventricles: 4.6 ± 0.4 ms; 4.5 ± 0.3 ms; 4.7 ± 0.2 ms; 
4.7 ± 0.3 ms and 4.8 ± 0.3 ms, respectively).
2.7 | Microelectrode recordings of AP characteristics
Reductions of Na+ current of the kind described above have been as-
sociated with corresponding reductions in maximum action potential 
upstroke rate, (dV/dt)max in turn resulting in the pro- arrhythmic slow-
ing of AP conduction32 reported in previous explorations of effects 
of Epac modulation.19 Figures 7 and 8 illustrate typical traces of atrial 
and ventricular action potential waveforms in response to regular 
F IGURE  6 Time course of ventricular Na+ current recovery from inactivation. (Aa) Pulse protocols used to investigate the time course of Na+ 
current recovery from inactivation (Ab) Recovery of Na+ currents with time after inactivation. A pipette of tip diameter 28 μm was used to obtain 
the currents shown in (b). (B) Families of recovery currents recorded (a) when no drug was present (pretreatment), (b) in the presence of 8- CPT 
(1 μmol/L), (c) in the presence of a combination of 8- CPT (1 μmol/L) and dantrolene (10 μmol/L) after the addition of 8- CPT, (d) after the addition 
of dantrolene (10 μmol/L), and (e) in the presence of a combination of 8- CPT (1 μmol/L) and dantrolene (10 μmol/L). (d) and (e) were obtained 
following direct introduction of pharmacological agents following pretreatment conditions in the absence of any preceding application of 8- CPT. 
(C) Dependences of Na+ current recovery (mean ± SEM) with recovery time before and following pharmacological challenge. The graphs show 
results (a) before and (b) following introduction of 8- CPT followed by (c) a combination of 8- CPT and dantrolene, (d) dantrolene alone and (e) a 
combination of 8- CPT and dantrolene
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6 Hz pacing (A) and their first derivatives whose peaks reflect (dV/
dt)max (B). In comparison with (i) untreated atrial (Figure 7) and ven-
tricular cardiomyocytes (Figure 8), (ii) 8- CPT challenge reduced (dV/
dt)max. This was reversed by further addition of (iii) dantrolene, which 
when applied by itself (iv) similarly gave (dV/dt)max resembling those 
of untreated hearts.
Significant differences in both atrial and ventricular (dV/dt)max val-
ues were thus detected amongst findings obtained in the absence (atria: 
219.56 ± 9.64 V/s [n = 23]; ventricles: 174.11 ± 6.21 V/s [n = 17]), 
and following challenge with 8- CPT before (atria: 170.97 ± 9.78 V/s 
[n = 20]; ventricles: 128.64 ± 5.26 V/s [n = 14]), and following further 
addition of dantrolene (atria: 206.74 ± 10.47 V/s [n = 22]; ventricles: 
170.90 ± 4.16 V/s [n = 20]) and of dantrolene applied alone (atria: 
213.48 ± 6.39 V/s [n = 29]; ventricles: 189.70 ± 9.28 V/s [n = 20]) 
(atria: F = 5.41; P = .0018; ventricles: F = 12.98; P = 8.8 × 10−7). There 
were significant pairwise (dV/dt)max differences in cardiomyocytes 
studied before, and following 8- CPT challenge (atria: P = .002; ven-
tricles: P = .0002) but not following further addition of dantrolene 
(atria: P = .75; ventricles: P = .99) or addition of dantrolene alone (atria: 
P = .96; ventricles: P = .36). Thus, further addition of dantrolene re-
stored Na+ current previously reduced by 8- CPT (atria: P = .042; ven-
tricles: P = .0004; Figures 7C and 8C). The similar findings in both atrial 
and ventricular preparations thus paralleled corresponding observa-
tions in loose patch clamp Na+ currents. In contrast, resting membrane 
F IGURE  7 Analysis of atrial action potential waveforms. Intracellular recording of atrial action potential waveforms during regular 6 Hz 
pacing (A) and their first derivatives reflecting (dV/dt) (B) in (i) untreated cardiomyocytes, (ii) with 8- CPT challenge followed by (iii) further 
addition of dantrolene, as well as (iv) dantrolene alone. These recordings yielded values of (dV/dt)max (C) that could be compared with remaining 
features of the resting potential (RMP) (D) and APD90 (E). Single, double and triple symbols denote significantly different pairs of values, to a 
significance value of P < .05, .01 and .001 respectively
(A)
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potentials showed no significant differences between groups (atria: 
F = 1.24, P = .30; ventricles: F = 1.18, P = .32), falling close to −75 mV 
in both atrial and ventricular cardiomyocytes (Figures 7D and 8D). 
Similarly, action potential durations at 90% recovery showed no sig-
nificant differences between experimental groups (atria: F = 2.10, 
P = .11; ventricles: F = 1.24; P = .296), falling close to ~35 and ~60 ms 
in atrial and ventricular cardiomyocytes respectively (Figures 7E and 
8E).
3  | DISCUSSION
The experiments here investigated for acute effects of Epac activa-
tion, known to acutely perturb cellular Ca2+ homeostasis,18 upon Na+ 
currents in wild- type murine cardiomyocytes. The loose patch clamp 
method detected current flowing into an electrode apposed to the 
extracellular surface of a fixed area of intact cell membrane, yield-
ing membrane currents normalised to the area of voltage- clamped 
cell surface (pA/μm2). In contrast, conventional patch clamp meth-
ods typically normalise measured currents to background membrane 
capacitance (pA/pF). Atrial and ventricular cells showed differing 
Na+ current magnitudes (e.g. ~−42.6 ± 2.9 vs −27.5 ± 1.8 pA/pF;39 
~−89.59 ± 41.05 vs −50.20 ± 3.34 pA/pF respectively40), but total 
membrane capacitances differing in the opposite direction (~43 vs 
~90 pF).39 Their total capacitances also differ in their relative con-
tributions of surface to tubular membrane41,42 that in turn express 
differing channel densities.43,44 Nevertheless, the loose- patch clamp 
permitted cardiomyocyte recordings to be made in intact superfused 
atrial and ventricular preparations, avoiding disruptions of intracellular 
Ca2+ homeostasis necessitated by the isolation and intracellular Ca2+ 
chelation otherwise required in conventional whole- cell patch- clamp 
recordings.30,31 Loose- patch clamp recordings also allowed employ-
ment of in vivo rather than reduced extracellular [Na+] levels sparing 
Na+- Ca2+ exchange. Previous reports had identified early inward cur-
rents obtained with this technique with Na+ currents mediating action 
potential (AP) conduction and upstroke.21
The experiments followed directly from findings that acute Epac 
(exchange protein directly activated by cAMP) activation: (i) produced 
phosphokinase A (PKA)- independent activation of RyR2- mediated 
Ca2+ release,13–15 increasing Ca2+ spark frequencies in adult rat cardio-
myocytes,16 Ca2+- dependent Ca2+ release amplitudes after isoprotere-
nol treatment,17 and amplitudes and frequencies of spontaneous Ca2+ 
release in mouse ventricular cardiomyocytes.18 It correspondingly, (ii) 
increased incidences of both triggered activity and ventricular tachy-
cardia (VT).18 However, it also (iii) associated such pro- arrhythmic ef-
fects with decreased conduction velocities.19 Furthermore, (iv) these 
electrophysiological characteristics were rescued by the RyR2- Ca2+ 
release channel blocker dantrolene, despite (v) all these changes being 
associated with unaltered recovery characteristics as reflected in the 
cardiac action potential (AP) durations and ventricular effective refrac-
tory periods.18,19
Such findings suggest that acutely altered Ca2+ homeostasis might 
result in arrhythmic substrate arising from delayed conduction, as 
previously suggested for the pro- arrhythmic Brugada syndrome1–5 
in contrast to the recovery abnormalities associated with the LQT 
syndromes.6,45 The pro- arrhythmic effects of acute abnormalities in 
cardiomyocyte Ca2+ homeostasis provoked by adrenergic stimulation, 
caffeine- mediated RyR2 stimulation10 or modified extracellular Ca2+ 
entry,11,12 have hitherto been primarily associated with arrhythmic 
triggering by delayed afterdepolarisation effects arising from the con-
sequently altered Na+–Ca2+ exchanger activity.
Early Na+ current is a primary determinant of cardiac AP conduc-
tion velocity. The present experiments are the first time Na+ current 
measurements have been made during Epac activation using an ex-
perimental design that permits comparisons with those previous 
studies.20,21,26 Thus, in addition to employing similar methods of Na+ 
current measurement: (i) They also (cf.18) investigated effects of Epac 
activation using the agonist 8- CPT13 at ~1 μmol/L, a concentration 
range known to provide a 300- fold preferential selectivity for Epac 
over PKA pathways;13,33,34 8- CPT only inhibits phosphodiesterase iso-
forms at considerably higher concentrations.35 (ii) The reversibility of 
the pharmacological effects of 8- CPT were tested for by the RyR2- 
inhibiting agent dantrolene (cf.19) thought to stabilize RyR2 closed 
states by enhancing interactions between its N- terminal and the cen-
tral domains particularly under conditions of increased open channel 
probability.36,37,46 Dantrolene thus inhibits RyR2- mediated diastolic 
Ca2+ release and decreases frequencies and durations of aberrant Ca2+ 
sparks in cardiomyocyte models for CPVT36 and cardiac failure.37,38 
(iii) Effects of dantrolene were further controlled for in experiments 
involving direct exposure to dantrolene, both by itself and in combi-
nation with 8- CPT (cf.19), and (iv) The experiments similarly measured 
the time courses and steady- state voltage- dependences of Na+ cur-
rent activation and inactivation (cf.21), in both atrial and ventricular 
preparations from WT murine hearts.
The variation of the test step to voltage V1 allowed measurement 
of the peak amplitudes of Na+ current and yielded current- voltage 
activation relationships. These peaks were followed by decays to a 
steady- state inactivation level whose dependence upon the voltage 
V1 was assessed by further voltage steps to a standard depolarised 
voltage V2. 8- CPT markedly reduced the Na
+ currents in both proce-
dures. The inhibitory effect of 8- CPT was reversed by further addition 
of dantrolene. In contrast, transfer of cardiomyocytes from pretreat-
ment conditions to solutions containing dantrolene alone or dantro-
lene combined with 8- CPT left the Na+ currents intact. Furthermore, 
detailed parameters describing the voltage dependence of current in-
activation were unchanged through these pharmacological conditions, 
as were the time courses of recovery from such inactivation.
These findings thus demonstrate that acutely altered Ca2+ homeo-
stasis following Epac- mediated RyR2- activation reversibly reduces 
Na+ channel function. Previous reversible manipulations of loose 
patch pipette [Na+] had identified early inward currents following step 
depolarisations with cardiomyocyte Na+ currents driving the maxi-
mum upstroke rate, (dV/dt)max, and in turn conduction of the cardiac 
action potential21. The present experiments accordingly went on to in-
vestigate such corresponding changes in action potential activation re-
flected in (dV/dt)max measurements from intracellular sharp electrode 
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recordings of membrane potential in intact atrial and ventricular 
preparations under comparable pharmacological conditions. The ob-
served (dV/dt)max were reduced with 8- CPT challenge; this effect was 
absent with dantrolene whether applied alone or in combination with 
8- CPT. This was in direct agreement with the observed changes in Na+ 
currents under corresponding pharmacological conditions. Together 
these findings implicate such Na+ current alterations with the pro- 
arrhythmic reductions in AP conduction velocity observed in previous 
explorations of the effects of Epac modulation in murine hearts.19
The present findings thus implicate conduction velocity sec-
ondary to compromised Na+ current as a source for arrhythmic 
substrate under conditions of acutely perturbed cytosolic Ca2+ 
homeostasis, reconstructing the altered conduction previously 
reported in Nav1.5 haplo- insufficient, Scn5a
+/− murine models for 
Brugada Syndrome.1–5 They also complement previous findings in 
murine hearts chronically modelling catecholaminergic polymor-
phic ventricular tachycardia (CPVT). Cardiomyocytes in the latter 
systems similarly showed diastolic episodes, or propagating waves, 
of RyR2- mediated Ca2+ release, as well as afterdepolarisation and 
triggering phenomena.8,9 RyR2- P2328S hearts additionally showed 
parallel reductions in atrial21 and ventricular action potential con-
duction velocities, the latter particularly following catcholaminergic 
challenge.20 These changes accompanied chronically downregu-
lated Nav1.5 expression.
21,27 Furthermore, WT rat cardiomyocytes 
increased their expression of functionally active surface membrane 
Nav1.5, Nav1.5 mRNA and total Nav1.5 protein following verapamil 
F IGURE  8 Analysis of ventricular action potential waveforms. Intracellular recording of ventricular action potential waveforms during regular 
6 Hz pacing (A) and their first derivatives reflecting (dV/dt) (B) in (i) untreated cardiomyocytes, (ii) with 8- CPT challenge followed by (iii) further 
addition of dantrolene, as well as (iv) dantrolene alone. These recordings yielded values of (dV/dt)max (C) that could be compared with remaining 
features of the resting potential (RMP) (D) and APD90 (E). Single, double and triple symbols denote significantly different pairs of values, to a 
significance value of P < .05, .01 and .001 respectively
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challenge and decreased their surface membrane Nav1.5 expres-
sion following calcimycin challenge.47,48 In parallel with the pres-
ent findings, RyR2- P2328S cardiomyocytes also demonstrated 
acutely reduced Nav1.5 function.
20,21,26 This was partially rescued 
by pharmacological interventions reducing RyR2- mediated Ca2+ 
release.22–25 These findings together suggest direct effects of al-
tered cytosolic [Ca2+] upon Nav1.5 function.49–51 Certainly, patch- 
clamped WT myocytes show respective reductions, or increases in 
Na+ current and (dV/dt)max, with increases in, or sequestration of, 
the pipette [Ca2+].52 Structural evidence suggests direct and/or in-
direct Ca2+ binding sites on Nav1.5 whose occupancy might modify 
Nav1.5 channel function. Close to the Nav1.5 carboxy- terminal, di-
rect Ca2+ binding occurring at an EF hand motif may increase Na+ 
channel activity.53 In contrast, an additional indirect ‘IQ’ domain 
binding site permits Ca2+/calmodulin (CaM) binding. Finally, multi-
ple phosphorylatable sites in the DI- II linker region, including ser-
ines 516 and 571, and threonine 594, are targeted by calmodulin 
kinase II (CaMKII)54–56. The latter two binding mechanisms require 
prior Ca2+ binding to EF hand motifs in Ca2+/CaM or CaMKII and 
compromise Na+ channel activity.50,51
4  | MATERIALS AND METHODS
4.1 | Solutions
Krebs–Henseleit (KH) solution was prepared (mmol/L: NaCl, 119; 
NaHCO3, 25; KCl, 4.0; KH2PO4, 1.2; MgCl2, 1.0; CaCl2, 1.8; glucose, 
10; and Na- pyruvate, 2.0; pH adjusted to 7.4 and bubbled with 95% 
O2/5% CO2 (British Oxygen Company, Manchester, UK)) for all tissue 
preparations. Chemical agents were purchased from Sigma- Aldrich 
(Poole, UK) unless otherwise stated. A modified KH solution contain-
ing 10 mmol/L 2,3- butanedione monoxime (BDM) and 10 μmol/L 
blebbistatin (Cayman Chemical Company, Ann Arbor, MI, USA) was 
also prepared for Langendorff perfusion of isolated hearts to electro-
mechanically uncouple the heart prior to isolation of right ventricular 
preparations. KH solution containing 8- (4- chlorophenylthio)adeno-
sine 3′,5′- cyclic monophosphate sodium salt (8- CPT, 1 μmol/L) and/
or dantrolene (10 μmol/L) (LKT Laboratories Inc, St Paul, MN, USA) 
was prepared and filtered to remove particles greater than 10 μm in 
diameter with standard filtration paper (Millipore, Bedford, MA, USA).
4.2 | Tissue preparation
This research has been regulated under the Animals (Scientific 
Procedures) Act 1986 Amendment Regulations 2012 following 
ethical review by the University of Cambridge Animal Welfare and 
Ethical Review Body (AWERB). It also conformed to the Guide for 
the Care and Use of Laboratory Animals, U.S. National Institutes of 
Health (NIH Publication No. 85- 23, revised 1996). C57BL6 WT mice 
aged 3- 6 months were used in all experiments. Mice were housed at 
room temperature in a licensed facility, allowed free access to ster-
ile rodent chow and water, and subjected to 12 hours light/dark cy-
cles. Mice were killed by cervical dislocation (Schedule 1 of the UK 
Animals (Scientific Procedures) Act 1986), following administration 
of 200 IU intraperitoneal heparin (ACROS Organics. ThermoFisher, 
Loughborough, Leicestershire, UK) 10 minutes prior to death. The 
heart was immediately excised and transferred into ice- cold KH solu-
tion. The aorta was cannulated with a trimmed and filed 21G hypoder-
mic needle, and secured onto the cannula with an aneurysm clip and 
5- 0 braided silk suture. The heart was then perfused retrogradely in 
a Langendorff system under constant flow (2 mL/min) by a Watson- 
Marlow (Falmouth, UK) peristaltic pump with 75 mL KH- BDM/blebbi-
statin solution to electromechanically uncouple the heart. Following 
cessation of contractions, the heart was immediately transferred into 
ice- cold KH- BDM/blebbistatin solution. For the loose patch clamp ex-
periments, the atria and right ventricle were dissected from the rest 
of the heart, mounted onto Sylgard (Dow Chemical Company, Staines, 
UK) then placed in the bath containing filtered KH buffer solution 
maintained at 27°C. Experiments performing intracellular electro-
physiological measurements transferred the hearts to a Langendorff 
perfusion system for the electrophysiological studies described below.
4.3 | Loose patch clamp recording
Pipettes were pulled from borosilicate glass capillaries (GC150- 10 
specification Harvard Apparatus, Cambourne, Cambridge, UK) using a 
micropipette puller (Flaming/Brown micropipette puller; model P- 97, 
Sutter Instrument Co. Novato, CA, USA). Pipettes were then mounted 
under a microscope at 250× magnification with a calibrated eyepiece 
graticule, and fractured with a diamond knife under visual control. 
Transverse force applied to the distal tip of the pipette resulted in 
fracture perpendicular to the axis of the micropipette. Selected pi-
pettes were fire- polished using an electrically heated nichrome fila-
ment under visual guidance at 400× magnification. The pipette tips 
were then bent to ~45° from the shaft of the pipette to allow the 
membrane to be approached vertically when mounted on the re-
cording amplifier headstage. Maximum internal tip diameters were 
measured at 1000× magnification. All pipettes were of 28- 32 μm in 
diameter following polishing.
The distal half of the micropipettes were filled with KH buffer and 
mounted onto a pipette holder connected to a headstage. Connection 
of an air filled line to the pipette holder allowed for application of suc-
tion through a syringe to form membrane seals. Ag/AgCl electrodes 
maintained electrical connections to the organ bath and pipette. 
Loose patch- clamp experiments were performed as previously de-
scribed.21,24,27 The pipette was lowered onto the membrane surface 
and gentle suction applied to allow seal formation around the patch of 
membrane. Voltage- clamp steps were delivered under computer con-
trol relative to the resting membrane potential. The loose patch clamp 
method applies voltage steps to the extracellular surface of membrane 
within the seal. Positive and negative voltage steps applied through 
the pipette respectively hyperpolarise and depolarise the membrane 
potential relative to the initial cell resting membrane potential (RMP). 
In the text membrane potentials are therefore stated in terms of their 
displacement from the RMP in the same convention adopted by earlier 
studies using this technique.29,57 The loose patch clamp configuration 
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results in larger leakage currents than the conventional patch clamp 
due to the comparatively low seal resistance. A custom- built ampli-
fier was used to compensate for the majority of the leakage current, 
series resistance errors and the displacement current through the pi-
pette capacitance.28 Residual leakage and capacitative currents were 
corrected for using reference records from subsequent P/4 control 
protocols applying steps whose amplitudes were scaled down by a 
factor of four and of the opposite sign relative to the test steps, as 
fully described previously.29,57
Experiments were first performed under pretreatment condi-
tions using preparations superfused with KH solution. Measurements 
were then made with KH solution containing 8- CPT (1 μmol/L), then 
with KH solution containing both 8- CPT (1 μmol/L) and dantrolene 
(10 μmol/L). To control for effects of dantrolene, further experiments 
superfused preparations with KH solution containing dantrolene 
(10 μmol/L) both alone and in combination with 8- CPT (1 μmol/L). 
Patch- clamp studies took place under standardised electrophysiolog-
ical conditions following similar intervals after each solution change. 
Each patch was subject only to a single application of the pulse pro-
tocols. These made differences between results attributable to pro-
longed changes in the patch such as bleb formation unlikely.58
4.4 | Whole heart intracellular 
microelectrode recordings
Microelectrode studies were performed using a modified horizontal 
Langendorff perfusion system incorporating a light microscope (ob-
jective ×5, eyepiece ×5, W. Watson and Sons Limited, London, UK), 
and warmed tissue chamber housed within a Faraday cage. Stimulating 
and recording electrodes were positioned on the heart using micro-
manipulators (Prior Scientific Instruments, Cambridge, UK). Sharp mi-
croelectrodes drawn from borosilicate glass pipettes (OD 1.2 mm, ID 
0.69 mm, Harvard Apparatus, Cambridge, UK) using a homebuilt mi-
croelectrode puller, filled with 3 M KCl (tip resistance 15- 25 MΩ), and 
mounted onto a right- angled microelectrode holder containing a Ag/
AgCl half- cell were connected to a high- input impedance direct- current 
microelectrode amplifier system (University of Cambridge, Cambridge, 
UK). Following band- pass filtering (between 0 and 2 kHz), signals were 
subject to analogue- to- digital conversion for recording at a sampling 
frequency of 10 kHz (1401; Spike software: Cambridge Electronic 
Design, Cambridge, UK). Impalements were consistently made in the 
proximal left ventricle to minimise confounds from regional variations 
in AP characteristics. Intracellular voltages were measured relative to 
that of a bath Ag/AgCl reference electrode. Impalements were used 
for detailed recordings where they resulted in abrupt appearance of a 
resting membrane potential (RMP) between −65 and −90 mV and APs 
of normal amplitude >75 mV. Hearts were paced by a bipolar platinum- 
coated stimulating electrode (NuMed, New York, USA) applied to the 
right ventricle lateral surface using a DS2A- Mk.II stimulator (Digitimer, 
Welwyn Garden City, Herts., UK) applying a stimulus voltage twice di-
astolic excitation threshold plus 0.5 mV, at a regular 6 Hz pacing fre-
quency. Maximum rates of action potential depolarisation (dV/dt)max 
were obtained from the first time differential of the intracellular AP 
waveform. These were measured along with cardiomyocyte resting po-
tentials, RMP, with AP amplitude measured from the RMP to the peak 
AP voltage. Action potential duration was measured as the time from 
the AP peak to 90% repolarisation to baseline.
4.5 | Analysis of results
The currents obtained from the loose patch procedure are dimen-
sioned in units of current (nA). Subsequent analysis converted the 
units of current (nA) to current densities (pA/μm2) using the formula:
Current- voltage curves describing Na+ current activation and inactiva-
tion and current- time relationships plotting the recovery timecourse 
of Na+ current from inactivation were obtained from the correspond-
ing measurements of peak Na+ currents (means ± standard error of 
the mean [SEM]) in the relevant protocol (see Figure 1Aa). Peak Na+ 
currents, I, reflecting inactivation properties were empirically related 
to the inactivating voltage V = V1 by a Boltzmann function: I = Imax/
{1 + exp(V−V*/k)}. Peak currents obtained during determinations of 
the timecourse, T, of recovery from inactivation were described by 
the exponential function I = Imax(1−exp(−T/τ)). The curve- fitting pro-
cedures employed the open source fitting algorithms QtiPlot (Version 
0.9.9- rc9).
4.6 | Statistical analysis of results
Owing to the limited recording time permitted following establish-
ment of each loose patch,58 each pharmacological condition was 
tested using different patches giving unpaired comparisons of results 
obtained (i) before, and following (ii) 8- CPT treatment, (iii) 8- CPT 
followed by addition of dantrolene, (iv) 8- CPT combined with dan-
trolene, and (v) dantrolene alone initially using one- way analysis of 
variance (ANOVA) to an α < .05 significance level. Subsequent post-
hoc comparisons suggested by a presence of significant differences 
employed a Bonferroni method in view of its application to (i) a sub-
set of four rather than all possible pairwise comparisons with (ii) the 
number of contrasts to be estimated close to the number of factors 
(NIST/SEMATECH e-Handbook of Statistical Methods, http://www.itl.
nist.gov/div898/handbook/).
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